Sermorelin Benefits: Claims vs What Studies Show
Benefits people claim for Sermorelin, set against what published studies measured, and where no study exists.
- Strongest evidence
- Human RCT
- Human / animal studies
- 6 / 0
- in our evidence file (PubMed search, 11 Oct 2026)
- FDA status
- Compounded by prescription
Claimed benefits and what studies show
Each row is an area where people claim a benefit, with the strongest study we summarise behind it. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Claim | Best evidence | Studies (human / animal) | What was measured | Page |
|---|---|---|---|---|
| Men over 50 | Human RCT evidence, 4 of 4 | 2 / 0 | GH and IGF-I in old men; Body composition; Muscle strength | Evidence for men over 50 |
| Hormone balance | Human RCT evidence, 4 of 4 | 3 / 0 | GH and IGF-I in old men; Serum IGF-1; IGF-I | Evidence for hormone balance |
| Muscle growth | Human observational evidence, 3 of 4 | 2 / 0 | Serum IGF-1; Body composition; Muscle strength | Evidence for muscle growth |
| Testosterone | Human observational evidence, 3 of 4 | 1 / 0 | Serum IGF-1 | Evidence for testosterone |
| Weight loss | Human observational evidence, 3 of 4 | 1 / 0 | Body composition | Evidence for weight loss |
| Bodybuilding | Review only | 0 / 0 | Regulatory status and evidence for physique claims | Evidence for bodybuilding |
Strongest study per claim: Men over 50, The Journal of clinical endocrinology and metabolism 1992, PMID 1379256; Hormone balance, The Journal of clinical endocrinology and metabolism 1992, PMID 1379256; Muscle growth, American journal of men's health 2017, PMID 28830317.
What the studies measured
| Outcome | Result | Study type | Source |
|---|---|---|---|
| GH and IGF-I in old men | Two weeks of twice-daily GHRH injections reversed age-related decreases in GH and IGF-I in healthy old men; body composition was not measured. | Human RCTn = 10 | The Journal of clinical endocrinology and metabolism 1992, PMID 1379256 |
| Serum IGF-1 | Mean IGF-1 rose from 159.5 ng/mL at baseline to 239.0 ng/mL after combined GHRP/sermorelin therapy (retrospective, multi-peptide combination, no control). | Human observationaln = 14 | American journal of men's health 2017, PMID 28830317 |
| Body composition | Weight, BMI, waist-to-hip ratio, DEXA muscle and fat, muscle histology, glucose, insulin and lipids did not change. | Human uncontrolled trialn = 11 | Metabolism: clinical and experimental 1997, PMID 9005976 |
| Muscle strength | Two of six strength measures (upright row, shoulder press) and abdominal-crunch endurance improved; the other measures did not. | Human uncontrolled trialn = 11 | Metabolism: clinical and experimental 1997, PMID 9005976 |
| IGF-I | Nightly GHRH raised nocturnal GH release but IGF-I did not change. | Human uncontrolled trialn = 11 | Metabolism: clinical and experimental 1997, PMID 9005976 |
| Height velocity | Mean height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr at 6 months and 7.2 cm/yr at 12 months (open-label, no control group). | Human uncontrolled trialn = 110 | The Journal of clinical endocrinology and metabolism 1996, PMID 8772599 |
| Regulatory status and evidence for physique claims | The review notes no regulatory approval for physique- or performance-related indications of these peptides, including sermorelin. | Review | Frontiers in endocrinology 2026, PMID 42395176 |
| Geref availability (US) | The US maker announced discontinuation of Geref (recombinant GHRH, sermorelin) in July 2008. | Review | The Journal of clinical endocrinology and metabolism 2009, PMID 19509104 |
| Growth in GH-deficient children | Limited data suggest that once-daily subcutaneous sermorelin was effective in some prepubertal children with idiopathic GH deficiency. | Review | BioDrugs 1999, PMID 18031173 |
| Compared with somatropin | Increases in height velocity with subcutaneous sermorelin 30 microg/kg bodyweight per day were less than with once-daily subcutaneous somatropin 30 microg/kg bodyweight. | Review | BioDrugs 1999, PMID 18031173 |
Growth hormone, testosterone and hormone-balance claims
The growth-hormone claim is the best supported: short-term twice-daily GHRH injections reversed the age-related fall in GH and IGF-I in old men.[1]
The testosterone claim has no direct support: testosterone was only reported as lower at baseline in older men, and the abstract states no treatment effect on testosterone.[1]
In men on testosterone therapy, a combination of GHRP-6, GHRP-2 and sermorelin was followed by higher IGF-1; the paper describes the combination as possibly beneficial in men with wasting conditions.[2]
Muscle, strength, fat and bodybuilding claims
In a small trial of older men, 6 weeks of 2 mg nightly improved 2 of 6 strength measures and one endurance test.[3]
The same trial found no change in weight, body mass index or DEXA measures of muscle and fat, so the weight-loss and muscle-growth claims were not supported there.[3]
A recent narrative review sorts performance-enhancing peptides into evidence tiers and highlights uncertainty about putative performance and recomposition benefits.[5]
What it was actually used for
Its documented clinical use was diagnosing and treating growth hormone deficiency in children, where daily subcutaneous dosing raised height velocity in an open-label study.[4]
The branded GHRH product was discontinued in the United States by its only manufacturer, as a clinical review recounts.[6]
More on Sermorelin
Common questions
Is Sermorelin proven to work?
The strongest study we summarise for Sermorelin is human rct evidence, among 9 studies. A trial result is not an approval; see the legal status.
What does sermorelin do?
It stimulates the pituitary to release growth hormone.[7]
What is sermorelin used for?
In published clinical work, for diagnosing and treating growth hormone deficiency in children.[7]
What are the benefits of sermorelin for men?
Treatment in older men did not change weight, body mass index or DEXA measures of muscle and fat.[3]
More on Sermorelin
Sources
- 1Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.The Journal of clinical endocrinology and metabolism · 1992PMID 1379256Accessed 2 Oct 2026
- 2Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.American journal of men's health · 2017PMID 28830317Accessed 2 Oct 2026
- 3Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.Metabolism: clinical and experimental · 1997PMID 9005976Accessed 2 Oct 2026
- 4Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.The Journal of clinical endocrinology and metabolism · 1996PMID 8772599Accessed 2 Oct 2026
- 5The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Frontiers in endocrinology · 2026PMID 42395176Accessed 2 Oct 2026
- 6Clinical review: Is lack of recombinant growth hormone (GH)-releasing hormone in the United States a setback or time to consider glucagon testing for adult GH deficiency?The Journal of clinical endocrinology and metabolism · 2009PMID 19509104Accessed 2 Oct 2026
- 7Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 1999PMID 18031173Accessed 2 Oct 2026
- 8PubMed search: (sermorelin[tiab] OR Geref[tiab]) (34 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: (sermorelin[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab] OR "GHRH 1-29"[tiab]) AND (elderly[tiab] OR aging[tiab] OR "older adults"[tiab] OR adults[tiab]) AND (treatment[tiab] OR therapy[tiab] OR administration[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11PubMed search: (sermorelin[tiab] OR Geref[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (21 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
Found an error? Report a correction.